1.2 OMIM# of the diseases #249100 #260920 #142680 #607115 #611762 
Analytical methods

Comment:
Depending on countries and age of individuals predictive testing and risk assessment is allowed and performed or not. Prenatal diagnosis may be discussed in some cases of CINCA (CAPS). Depending on the quality of sequencing almost 100% for MEFV − , MVK − , TNFRSF1A − , NLRP3 − , and NLRP12 − genes
TEST CHARACTERISTICS
Analytical specificity (proportion of negative tests if the genotype is not present)
Depending on quality of sequencing almost 100% for MEFV − , MVK − , TNFRSF1A − , NLRP3 − , and NLRP12 − genes
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if quantification can only be made case by case.
There are many causes for recurrent fever attacks; hence, it is difficult to define a clinical sensitivity. In cases where two mutations are identified, for example, the MEFV gene, it is presumed, because of high analytical sensitivity, that the patient has FMF.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if quantification can only be made case by case.
There are many causes for recurrent fever attacks; hence, it is difficult to define a clinical specificity. In cases where no mutation is identified, for example, in the MEFV gene, it is presumed, because of high analytical specificity, that the patient has not FMF due to mutations in the MEFV gene, but it does not exclude a clinical diagnosis of FMF, and hence a corresponding treatment has not to be excluded.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
All these monogenic autoinflammatory syndromes (FMF, MKD, TRAPS, CAPS, and FCAS2) are children's diseases, hence adult onset is unusual. However, the FMF patients carrying the homozygous p.Met694Val genotype have obviously higher life time risk to develop amyloidosis. 8 2.6 Negative clinical predictive value (probability not to develop the disease if the test is negative) Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
There are many causes for recurrent fever attacks; hence it is difficult to define a negative clinical predictive value. For example, in cases where no mutation is identified in the MEFV gene, it is presumed, because of high analytical specificity, that the patient does not have FMF at least due to mutations in the MEFV gene, but it does not exclude a clinical diagnosis of FMF from criteria described by Livneh et al. 3. CLINICAL UTILITY 3.1 (Differential) diagnostics: the tested person is clinically affected (To be answered if in 1.9 'A' was marked) 
Prenatal diagnosis
(To be answered if in 1.9 'D' was marked) 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Yes, by knowing the mutations prenatal diagnosis will be possible, but only in some cases of CINCA (CAPS) prenatal diagnosis may be discussed.
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe)
